@FiercePharma: Sanofi, Merck, others said to be eyeing Bausch buyout. Story | Follow @FiercePharma
> Six people were hospitalized Tuesday after a leak at a Novartis ($NVS) drug plant near Basel. Story
> Pfizer ($PFE) is raising about $27.7 million in a deal to sell and lease back its Swedish headquarters in Stockholm. Item
> Pfizer has agreed to pay $55 million to resolve charges of marketing violations against Wyeth for the acid reflux drug Protonix. Story
> India drug exports grew by more than 23% in the last fiscal year. Item
> The EU has voted to put patents on sale, cutting costs by about 80%. Story
@FierceMedDev: Medtronic facing federal suit from 'exploited' patients. Story | Follow @FierceMedDev
@MarkHFierce: Cerapedics pulled in a $19M Series C for its bone graft development work. New investors include MedImmune. More | Follow @MarkHFierce
@DamianFierce: Welch Allyn isn't done reorganizing. After announcing plans to cut 275 jobs, it's moving its Euro HQ. Article | Follow @DamianFierce
> Myriad, Sanofi to team on diabetes biomarker Dx discovery work. Item
> BG Medicine gains CE mark for cardiovascular Dx. News
Biotech News
@FierceBiotech: Nuron acquires Pfizer's meningitis vaccine. Story | Follow @FierceBiotech
@JohnCFierce: What does Lilly have? A signal, unconfirmed, that solanezumab works in mild Alzheimer's. See you in 3-4 years, alongside much competition. | Follow @JohnCFierce
@RyanFierce: $GILD wants a piece of the big oncology pie, as it showed with the Yale deal last year. YM could get it there sooner. Report | Follow @RyanMFierce
> GlaxoSmithKline backs upstart's $17M A round for therapy against bulging-eye ailment. Article
> Eli Lilly ditches FDA filing for Alzheimer's hope solanezumab. News
Drug Delivery News
> Eleven's lead topical eye drug completes PhIa, enters PhIb trials. Report
> Silver bullet targets antibiotics to deep infections. News
> Porcupine quills point to less painful shots. Story
> Sirtex, SingHealth develop stealth cancer treatments. Article
> Alnylam plans clinical trials for RNAi therapeutic. More
And Finally... Records from the U.S. House show that Ranbaxy Laboratories, the Indian generics maker that last year signed a 5-year consent decree with U.S. authorities, paid $90,000 to a lobbying firm. Ranbaxy has paid $90,000 to lobbyists Patton Boggs to work such angles as preserving "Access to Affordable Generics," according to a document registered in 2010. Story